About Generate Biomedicines
Generate Biomedicines is a biotechnology company at the forefront of applying generative artificial intelligence to therapeutic protein design and drug discovery. The company has developed a proprietary generative biology platform that uses machine learning to create novel protein therapeutics from scratch, rather than modifying existing proteins. This approach enables the design of proteins with specific therapeutic properties tailored to address unmet medical needs. Generate Biomedicines' technology platform combines deep learning, structural biology, and computational protein design to generate and optimize therapeutic candidates across multiple modalities including antibodies, peptides, and other protein-based drugs. The company's mission is to expand the druggable proteome and accelerate the development of breakthrough medicines. By leveraging generative AI, Generate Biomedicines aims to design proteins that are difficult or impossible to create using traditional methods, potentially unlocking new therapeutic opportunities across various disease areas. The company serves the biopharmaceutical industry and is developing its own pipeline of therapeutic candidates while also partnering with pharmaceutical companies to apply its platform to their drug discovery programs.
Mission & Story
Mission
Democratizing biotherapeutics and pioneering generative biology to create breakthrough medicines
Founding Story
Co-founded by Gevorg Grigoryan (Chief Technology Officer) and backed by Flagship Pioneering, founded by Noubar Afeyan who serves as Chair of the Board. The company broke from convention to eliminate barriers between computation and biology.
Who It Serves
Milestones & Awards
Recent Milestones
Initiated global Phase 3 studies of GB-0895 for severe asthma. Reported Q1 2026 financial results. Expanded to 140,000+ square feet across Boynton Yards (Somerville) and Andover locations. Participated in Goldman Sachs 47th Annual Global Healthcare Conference (May 2026).
Company Details
- Headquarters
- Somerville, MA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.